MYCN and neoplasm: Strikingly, however, tumor incidence increased to 100% (8/8) and median survival was reduced to 107 d in R26IGF2BP1/MYCN mice, validating a strong synergy of IGF2BP1 and MYCN in promoting neuroblastoma (Fig. 6a).